Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMX-8 for Anemia in ESRD on Hemodialysis
NCT01873534Phase 2Terminated
- Sponsor
- FerruMax Pharmaceuticals, Inc.
- Start
- Jun 2013
- Primary completion
- Mar 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of FMX-8 in anemia of chronic disease (ACD) (3 arms), sponsored by FerruMax Pharmaceuticals, Inc. Primary endpoints: Proportion of subjects who achieve an increase in Hgb >= 1g/dL or continuing rise at 8 weeks, Number and Severity of Adverse Events at 8 weeks and 2 more. Started Jun 2013; status: terminated.
02
Drugs
FMX-8
03
Conditions
anemia of chronic disease (ACD)
Beyond the preview
Go deeper on NCT01873534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01873534.